A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

Official Title

A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

Summary:

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

Trial Description

Primary Outcome:

  • Adverse Event(s)
  • Non-Tolerated Dose (NTD)
  • Maximum Tolerated Dose (MTD)
  • Dose-Limiting Toxicity (DLT)
Secondary Outcome:
  • Overall response rate (ORR)
  • Time to response (TTR)
  • Duration of response (DOR)
  • Progression free survival (PFS)
  • Overall survival (OS)
  • Pharmacokinetic - Cmax
  • Pharmacokinetic - Cmin
  • Pharmacokinetic - AUC
  • Pharmacokinetic - tmax
  • Pharmacokinetic - t1/2
  • Pharmacokinetic - CL
  • Pharmacokinetic - Vss
  • Anti-CC-95251 antibody (ADA) assessment
Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B & Part C), first-in-human clinical study of CC-95251 in subjects with advanced solid & hematologic cancers. The dose escalation part (Part A) of the study will be conducted in three stages. Stage 1 will evaluate the safety and tolerability of escalating doses of CC-95251, administered IV, to determine the maximum tolerated dose (MTD), non-tolerated dose (NTD), and/or recommended Phase 2 dose (RP2D) of CC-95251. Stage 2 will evaluate the safety and tolerability of escalating doses of CC-95251 in combination with weekly cetuximab, both administered IV, to determine the MTD, NTD, and/or RP2D of CC-95251 plus cetuximab. Stage 3 will evaluate the safety and tolerability of escalating doses of CC-95251 in combination with rituximab, both administered IV, to establish MTD, NTD, and/or RP2D of CC-95251 plus rituximab.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society